Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Research Type: Articles

Sort 1 results by:

Filter Applied. Clear All

Latest Posts

April 6, 2026 Primer: Risks and Complications of Drug-Induced Abortion Primer: Risks and Complications of Drug-Induced Abortion April 1, 2026 Abortion Reporting: Iowa (2024) Abortion Reporting: Iowa (2024) March 31, 2026 Fact Sheet: Health Insurance Coverage of Elective Abortion Fact Sheet: Health Insurance Coverage of Elective Abortion
Reset All Filters
United Kingdom Data Deficiencies Influencing U.S. FDA Decisions
Life & the Law

United Kingdom Data Deficiencies Influencing U.S. FDA Decisions

CLI's VP of Medical Affairs Ingrid Skop, together with Calum Miller, MD, and Kevin Duffy, MPH, recently published an article in Issues in Law & Medicine arguing that decisions by the FDA to pull back regulations on the abortion drug mifepristone in part relied on "flawed studies with significantly undercounted complications" from the U.K.

Life & the Law

Misleading Statements About “Life of the Mother” Exceptions in Pro-life Laws Require Correction

Recently CLI scholars Ingrid Skop, M.D. and Mary Harned, J.D. published a rebuttal in Issues in Law & Medicine to a series of misleading statements made in an article that appeared in the journal Obstetrics & Gynecology.

New Study Reveals FDA Relied on Cherrypicked Data to Approve Dangerous Mail-Order Abortion Drugs
Abortion Drugs

New Study Reveals FDA Relied on Cherrypicked Data to Approve Dangerous Mail-Order Abortion Drugs

A new peer-reviewed article highlights major flaws in the data used by the U.S. Food and Drug Administration (FDA) to remove medical safeguards and in-person administering of abortion drugs. These flaws illustrate the ongoing problem of lack of quality abortion reporting data in the U.S. as well as in the United Kingdom.

Maternal & Public Health

Abortion Reporting: Oklahoma (2023)

Oklahoma reported zero abortions in 2023 as of May 8th, 2024. 

New Study: Abortion Increases Risk of Cardiovascular Diseases
Maternal & Public Health

New Study: Abortion Increases Risk of Cardiovascular Diseases

A new longitudinal peer-reviewed study by the Charlotte Lozier Institute has shown that abortions are an independent risk factor for increased risk of cardiovascular diseases (CVD), the leading cause of death among women.

Maternal & Public Health

Abortion Reporting: Florida (2023)

Florida publishes some of its abortion reporting tables on the state’s Agency for Health Care Administration (ACHA) website. The full report was provided to the Charlotte Lozier Institute (CLI) upon request in March 2024. This is CLI’s first published summary of a state’s 2023 abortion statistics.

Scientists to SCOTUS: FDA Harms Women & Doctors by Allowing Dangerous Mail-Order Abortion Drugs
Abortion Drugs

Scientists to SCOTUS: FDA Harms Women & Doctors by Allowing Dangerous Mail-Order Abortion Drugs

As the nation’s leading pro-life scientific, statistical and research center, the Charlotte Lozier Institute has filed an amicus brief asking the Supreme Court to affirm the 5th U.S. Circuit Court of Appeals decision that found the FDA likely violated the law when it loosened safeguards on abortion drugs by allowing them to be sent by mail.

Effects of prior reproductive losses on risk of cardiovascular diseases within six months of a first live birth
Maternal & Public Health

Effects of prior reproductive losses on risk of cardiovascular diseases within six months of a first live birth

There is emerging evidence suggesting that pregnancy loss (induced or natural) is associated with an increased risk of cardiovascular diseases (CVD). This prospective longitudinal study investigates the effect of prior pregnancy losses on CVD risk during the first six months following a first live birth.

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image